FdaApplication
NDA 021318
Identifiers
- fda_app_no: NDA021318
Properties
| Property | Value |
|---|---|
| applicant_name | ELI LILLY AND CO |
| application_type | NDA |
| approval_date | 2002-11-26 |
Revenue by product
FORTEO
| Period | Revenue |
|---|---|
| Q3 2024 | $118.1M |
| Q2 2024 | $69.9M |
| Q1 2024 | $61.3M |
| Q4 2023 | $116.4M |
| Q3 2023 | $146.4M |
| Q2 2023 | $148.0M |
| Q1 2023 | $122.3M |
| Q4 2022 | $160.1M |
| Q3 2022 | $177.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| FORTEO | TERIPARATIDE | 0.56MG/2.24ML (0.25MG/ML) | SOLUTION;SUBCUTANEOUS |
| FORTEO | TERIPARATIDE | 0.75MG/3ML (0.25MG/ML) | SOLUTION;SUBCUTANEOUS |
2 products